Athira Pharma, Inc. is implementing a 10-for-1 reverse stock split of its common stock.
The reverse stock split is set to take effect on September 17, 2025, with trading on a split-adjusted basis starting on September 18, 2025.
This strategic move is aimed at increasing the share price to meet Nasdaq's minimum bid price requirement and attracting a wider range of investors.
Purpose of Reverse Stock Split
To increase the price per share, comply with Nasdaq listing requirements, and enhance marketability.
Impact on Stockholders
Each 10 shares will be merged into 1 share, reducing the total authorized shares to 90,000,000.
Changes to Equity Incentive Plans
Proportional adjustments will be made to options, restricted stock units, and equity incentive plans.
- The reverse stock split aims to improve liquidity and market appeal for Athira's common stock.
- It aligns with the company's strategy to generate greater investor interest and ensure compliance with Nasdaq regulations.
Athira Pharma's decision to implement a reverse stock split reflects its commitment to strengthening shareholder value and market positioning. This move sets the stage for potential growth and increased investor confidence in the company's future prospects.